{"Acute myeloid leukaemia": 16.416231902655245, "Anaemia": 2.665708319608646, "Anaphylactic reaction": 3.154237107480918, "Anaphylactic shock": 2.5660765514582184, "Anaphylactoid reaction": 5.894912179903048, "Aphthous ulcer": 2.2152020209205, "Ascites": 4.495874422105774, "Back pain": 4.11807273787603, "Blood alkaline phosphatase increased": 2.0265810399343835, "Brain oedema": 2.2878285002293035, "Breast cancer metastatic": 13.844215625537611, "Bronchospasm": 6.762408595565901, "Candida infection": 2.6094743054828635, "Cardiogenic shock": 2.455242648088, "Cardiotoxicity": 20.606775732460548, "Cerebral toxoplasmosis": 51.55851123437852, "Chest discomfort": 2.7023220319057613, "Cyanosis": 3.905814382529029, "Dermatitis": 3.721657791427838, "Dermatitis bullous": 6.755571905295695, "Dermatitis exfoliative generalised": 2.9702628391934014, "Desmoplastic small round cell tumour": 354.2972950340737, "Diffuse large B-cell lymphoma": 14.31536208390516, "Diffuse large B-cell lymphoma recurrent": 20.610196016135923, "Diffuse large B-cell lymphoma refractory": 103.41626631044566, "Dilated cardiomyopathy": 6.819344488332185, "Disease progression": 6.799625397537933, "Dysgraphia": 6.83519294491055, "Ejection fraction decreased": 5.790505029138122, "Epstein-Barr virus infection": 8.937936264537738, "Erythema": 4.7065028340627375, "Extravasation": 24.702306206251336, "Febrile neutropenia": 8.438589942503333, "Feeling hot": 2.12627571503587, "Flushing": 12.435846694801675, "Gastric ulcer": 3.120830111855331, "Haematotoxicity": 12.74634902097489, "Haemorrhage intracranial": 2.6532110974691308, "Hepatitis cholestatic": 2.79778209103456, "Hepatotoxicity": 3.693891311750168, "Hypersensitivity": 4.083071907326811, "Hypertransaminasaemia": 2.337656610588982, "Hypoxia": 2.9732175357673745, "Infusion related reaction": 27.69827858036788, "Infusion site reaction": 16.34110469836217, "Interstitial lung disease": 14.952238530596354, "Intestinal obstruction": 4.048924344642032, "Laryngeal oedema": 4.306993799886247, "Leukopenia": 4.093935420241425, "Malignant neoplasm progression": 3.0948885531340853, "Mantle cell lymphoma recurrent": 129.70878503950638, "Metastases to bone": 3.441742769172808, "Metastases to liver": 7.25386423540664, "Metastases to lymph nodes": 9.765847469944289, "Metastases to peritoneum": 32.53880288847138, "Mouth ulceration": 2.9870909385078663, "Mucosal inflammation": 16.872895737343462, "Multiple-drug resistance": 7.648590483363011, "Myelodysplastic syndrome": 6.218518014670228, "Neoplasm progression": 6.484491072544475, "Neurological symptom": 3.571900301581749, "Neuropathy peripheral": 2.499008906285162, "Neurotoxicity": 2.080584492222345, "Neutropenia": 7.356037501308275, "Neutropenic sepsis": 9.34679140187509, "Neutrophil count increased": 4.85518163478879, "Off label use": 6.632555329667047, "Ovarian cancer": 27.03620824413983, "Palmar-plantar erythrodysaesthesia syndrome": 58.44418964901055, "Pancytopenia": 5.75086480447691, "Plasma cell myeloma": 6.550785786912292, "Plasma cell myeloma recurrent": 21.28066622512318, "Pneumonitis": 2.416346374017764, "Polyneuropathy": 4.035874746464884, "Post transplant lymphoproliferative disorder": 20.86388934609301, "Product use in unapproved indication": 15.357298762361864, "Progressive multifocal leukoencephalopathy": 11.182075505572945, "Second primary malignancy": 3.849320436811404, "Sense of oppression": 11.278713760496354, "Sepsis": 2.761768953368004, "Serous cystadenocarcinoma ovary": 699.3842590766859, "Skin exfoliation": 3.4631216770196502, "Skin hyperpigmentation": 9.01758605148926, "Skin lesion": 2.308551366460995, "Skin reaction": 4.8504101124817645, "Skin toxicity": 23.488090680243136, "Skin ulcer": 3.1359534856752225, "Smooth muscle cell neoplasm": 191.984106825042, "Stomatitis": 7.331746732032793, "Throat tightness": 2.1973748271421694, "Thrombocytopenia": 3.5205231337249354, "Toxic epidermal necrolysis": 2.360747061845563, "Toxic skin eruption": 7.479793148253372, "Transaminases increased": 2.8787783426659894}